Vascular diseases

Medical Vein Clinic Announces Expansion of Services to Treat Patients with Lymphatic Disease

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Angiology, Circulatory system, Vascular surgery, Varicose veins, Vein, Edema, Vascular diseases, Vein disorders

Dr. Trock will complement the clinic's varicose vein treatment experts, extending their services to care for patients suffering from lymphatic disease.

Key Points: 
  • Dr. Trock will complement the clinic's varicose vein treatment experts, extending their services to care for patients suffering from lymphatic disease.
  • He is dedicated to evaluating and educating patients along with developing home treatment plans to resolve vein pain and swelling associated with vein disease.
  • "Early detection and treatment of vein and lymphatic disease is critical to prevent patients from experiencing a decline in physical functions and becoming debilitated," noted Dr. John Hogg, founder of Medical Vein Clinic.
  • Medical Vein Clinic has treated thousands of patients with vein and lymphatic disease, helping them lead fuller, healthier lives.

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Retrieved on: 
Tuesday, June 1, 2021
Vascular diseases, Edwards Lifesciences, Hypotension, Acumen, Edwards, California, States of the United States, Industry economics)

IRVINE, Calif., June 1, 2021 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance.

Key Points: 
  • IRVINE, Calif., June 1, 2021 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance.
  • "The noninvasive Acumen IQ cuff provides the opportunity to reduce hypotension in a broader range of patients, including those who do not require an invasive arterial line.
  • The cuff, along with the predictive capabilities of Acumen HPI software to proactively manage hypotension, will have a meaningful impact on patients."
  • Edwards, Edwards Lifesciences, the stylized E logo, Acumen, Acumen IQ, HemoSphere, and HPI, are trademarks of Edwards Lifesciences Corporation.

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

The Lisa Foundation Appoints New Executive Director to Continue Leading the Fight Against Brain Aneurysms

Retrieved on: 
Tuesday, May 25, 2021
Vascular diseases, Aneurysm, Gross pathology

She is the first survivor to take over a leadership role for an organization in the Brain Aneurysm industry.

Key Points: 
  • She is the first survivor to take over a leadership role for an organization in the Brain Aneurysm industry.
  • "I am truly honored to continue Todd's mission of advocating and being a voice for the Brain Aneurysm community.
  • Debbie brings a strong background working in nonprofit to her new role at The Lisa Foundation.
  • The Lisa Foundation, a 501(c)(3), is a private funder of Brain Aneurysm initiatives that directly or indirectly support awareness, education, research and survivor support in the US.

Global Atherosclerosis Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Cardiology, Medical specialties, Cardiovascular system, Circulatory system, Vascular diseases, Atherosclerosis

b'The "Global Atherosclerosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Atherosclerosis Epidemiology and Patient Flow Analysis - 2021, provides Atherosclerosis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Atherosclerosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Atherosclerosis Epidemiology and Patient Flow Analysis - 2021, provides Atherosclerosis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Atherosclerosis patients, history of the disease at the population level (Atherosclerosis prevalence, Atherosclerosis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Atherosclerosis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Atherosclerosis market sizing, assessing market potential, and developing drug forecast models\nIdentify Atherosclerosis patients segments through age groups, gender, and disease sub-types\n'

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session

Retrieved on: 
Monday, May 17, 2021
Vascular diseases, Medical specialties, Clinical medicine, Medicine, Amarin Corporation, Atheroma, Atherosclerosis, Ethyl eicosapentaenoic acid, XC2

Percent atheroma volume (PAV) is identified as a robust prognostic marker of whole-heart atherosclerotic plaque characterization with CCTA.

Key Points: 
  • Percent atheroma volume (PAV) is identified as a robust prognostic marker of whole-heart atherosclerotic plaque characterization with CCTA.
  • Forty-nine patients (49% female; age 57.2 \xc2\xb1 9.2 years) with interpretable images for Fractional Flow Reserve Computed Tomography (FFRCT) were included.
  • While Amarin respects the scientific opinions of these clinicians and scientists, Amarin takes no responsibility for those opinions.
  • In addition to the United States, VASCEPA is approved and sold in Canada, Lebanon and the United Arab Emirates.

Insights on the Neurovascular Devices Global Market to 2029 - Increasing Ageing Population in the Developed Nations Will Drive Growth

Retrieved on: 
Tuesday, May 11, 2021
Medical specialties, Medicine, Health care, Interventional radiology, Vascular diseases, Embolization, Surgery, Aneurysm, Food and Drug Administration

Increasing demand for minimally invasive procedures, growing commonness of neurovascular disorders and stroke, rapid new product development and commercialization drive the overall neurovascular devices market growth.

Key Points: 
  • Increasing demand for minimally invasive procedures, growing commonness of neurovascular disorders and stroke, rapid new product development and commercialization drive the overall neurovascular devices market growth.
  • Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.
  • Furthermore, rapid commercialization of novel devices and strong pipeline candidates under the FDA scrutiny would further drive the U.S. and therefore North America market.
  • The high procedural costs along with the need for skilled professionals is restraining the overall market growth.

Shockwave Medical Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Clinical medicine, Medicine, Vascular diseases, Lithotripsy, Shockwave, Atherosclerosis, Coronary artery disease, Batman The Escape

The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and increased adoption of Shockwave products.\nGross profit for the first quarter of 2021 was $24.0 million compared to $9.5 million for the first quarter of 2020.

Key Points: 
  • The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and increased adoption of Shockwave products.\nGross profit for the first quarter of 2021 was $24.0 million compared to $9.5 million for the first quarter of 2020.
  • Gross margin for the first quarter of 2021 was 75%, as compared to 63% in the first quarter of 2020.
  • Net loss per share for the period was $0.68.\nCash, cash equivalents and short-term investments totaled $177.4 million as of March 31, 2021.\nShockwave Medical projects revenue for the full year 2021 to range from $195 million to $205 million, which would represent 188% to 202% growth over the company\xe2\x80\x99s prior year revenue.\nShockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, May 10, 2021 to discuss its first quarter 2021 financial results.
  • Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL).

Worldwide Neurovascular Devices Industry to 2029 - Featuring Penumbra, Phenox and Stryker Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Medical devices, Health, Medical specialties, Interventional radiology, Medicine, Clinical medicine, Vascular diseases, Aneurysm, Gross pathology, Embolization, Stroke, Stent, Neurovascular bundle, Alexander L. Coon

Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.

Key Points: 
  • Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.
  • As per the Internet Stroke Center statistics, around 75% of strokes take place in the age group of 60-65.
  • For example, with the introduction of new flow diversion stent technique, the need to treat complex aneurysms with bypasses has fallen down.
  • However, lack of skilled neurologists in hospitals is limiting the growth of neurovascular devices market.\n'

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

Retrieved on: 
Tuesday, May 4, 2021
Circulatory system, Cardiovascular diseases, Cardiovascular system, Heart diseases, Aging-associated diseases, Vascular diseases, Anatomy, Coronary arteries, Angina, Coronary artery disease, Atherosclerosis, Heart

Angina occurs when the heart muscle is not getting enough blood and therefore enough oxygen to work properly.

Key Points: 
  • Angina occurs when the heart muscle is not getting enough blood and therefore enough oxygen to work properly.
  • It is usually caused by hardening of the arteries.
  • Chronic angina, the most common symptom of coronary artery disease, can be a debilitating heart condition.
  • KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team\'s strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, our patients.